Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05743_nanopub.RAJYoZNVU3IVAbUU7Tx4c-gxhxAqK18BZTrGc9vQSR3PE#assertion>. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05743 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05743 label "MAP-0004 [drugbank:DB05743]" assertion.
- drugbank:DB05743 seeAlso DB05743 assertion.
- drugbank:DB05743 description "MAP-0004 is a proprietary orally inhaled version of dihydroergotamine, or DHE, intended to treat migraine. Study showed that MAP-0004 provided pain relief as early as within ten minutes of dosing, and that this relief was sustained through at least 24 hours. The study also demonstrated efficacy trends in treating nausea, photophobia and phonophobia. Based on these results, as well as independent research that concludes that patients prefer migraine therapies providing fast onset, pain relief, sustained pain relief and safety, the company believes that MAP-0004 has the potential to be a first-line therapy for migraine patients." assertion.
- drugbank:DB05743 identifier "drugbank:DB05743" assertion.
- drugbank:DB05743 title "MAP-0004" assertion.
- drugbank:DB05743 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05743 drugbank_vocabulary:drugbank-id "DB05743" assertion.
- drugbank:DB05743 bio2rdf_vocabulary:x-identifiers.org DB05743 assertion.
- drugbank:DB05743 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05743" assertion.
- drugbank:DB05743 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05743 bio2rdf_vocabulary:identifier "DB05743" assertion.